Literature DB >> 15665616

The evolution of accelerated, partial breast irradiation as a potential treatment option for women with newly diagnosed breast cancer considering breast conservation.

Frederick M Dirbas1, Stefanie S Jeffrey, Don R Goffinet.   

Abstract

Breast conservation therapy (BCT) is a safe, effective alternative to mastectomy for many women with newly diagnosed breast cancer. This approach involves local excision of the malignancy with tumor-free margins, followed by 5-7 weeks of external beam whole breast (WB) radiotherapy (XRT) to minimize the risk of an in-breast tumor recurrence (IBTR). Though clearly beneficial, the extended course of almost daily postoperative radiotherapy interrupts normal activities and lengthens care. Additional options are now available that shorten the radiotherapy treatment time to 1-5 days (accelerated) and focus an increased dose of radiation on just the breast tissue around the excision cavity (partial breast). Recent trials with accelerated, partial breast irradiation (APBI) have shown promise as a potential replacement to the longer, whole breast treatments for select women with early-stage breast cancer. Current APBI approaches include interstitial brachytherapy, intracavitary (balloon) brachytherapy, and accelerated external beam (3-D conformal) radiotherapy, all of which normally complete treatment over 5 days, while intraoperative radiotherapy (IORT) condenses the entire treatment into a single dose delivered immediately after tumor excision. Each approach has benefits and limitations. This study covers over 2 decades of clinical trials exploring APBI, discusses treatment variables that appear necessary for successful implementation of this new form of radiotherapy, compares and contrasts the various APBI approaches, and summarizes current and planned randomized trials that will shape if and how APBI is introduced into routine clinical care. Some of the more important outcome variables from these trials will be local toxicity, local and regional recurrence, and overall survival. If APBI options are ultimately demonstrated to be as safe and effective as current whole breast radiotherapy approaches, breast conservation may become an even more appealing choice, and the overall impact of treatment may be further reduced for certain women with newly diagnosed breast cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15665616     DOI: 10.1089/cbr.2004.19.673

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  3 in total

1.  A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: treatment planning and quality assurance.

Authors:  Yuki Otani; Takayuki Nose; Takushi Dokiya; Toshiaki Saeki; Yu Kumazaki; Shuuji Asahi; Iwao Tsukiyama; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Eisaku Yoden; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi
Journal:  Radiat Oncol       Date:  2015-06-04       Impact factor: 3.481

2.  Patterns of Recurrence Among Higher-Risk Patients Receiving Daily External Beam Accelerated Partial-Breast Irradiation to 40 Gy in 10 Fractions.

Authors:  Kelly Fitzgerald; Jessica Flynn; Zhigang Zhang; Zachary Cost; Boris Mueller; Erin F Gillespie; Beryl McCormick; Atif Khan; Oren Cahlon; Simon N Powell; Lior Z Braunstein
Journal:  Adv Radiat Oncol       Date:  2019-08-06

3.  Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.

Authors:  Jayant S Vaidya; Max Bulsara; Michael Baum; Frederik Wenz; Samuele Massarut; Steffi Pigorsch; Michael Alvarado; Michael Douek; Christobel Saunders; Henrik L Flyger; Wolfgang Eiermann; Chris Brew-Graves; Norman R Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Tammy Corica; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McCready; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; David J Joseph; Jeffrey S Tobias
Journal:  BMJ       Date:  2020-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.